NASDAQ:EDSA Edesa Biotech Q3 2026 Earnings Results & Report $3.51 -0.15 (-4.10%) Closing price 10/9/2026 04:00 PM EasternExtended Trading$3.64 +0.13 (+3.59%) As of 10/9/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Edesa Biotech missed analyst earnings expectations in its Q3 2026 results, released August 13, 2026. The company reported EPS of -$0.60 versus the -$0.4350 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2026Report DateAugust 13, 2026TimeAfter Market Closes Edesa Biotech EPS ResultsActual EPS-$0.60Consensus EPS -$0.4350Beat/MissMissed by -$0.1650One Year Ago EPSN/AEPS Beat Rate3 of last 8 quartersEdesa Biotech Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsEdesa Biotech's next earnings date is estimated for Friday, December 11, 2026, based on past reporting schedules. Conference Call ResourcesEarnings HistoryCompany Profile Edesa Biotech Q3 2026 Earnings FAQ Did Edesa Biotech beat earnings estimates for Q3 2026? Edesa Biotech (NASDAQ:EDSA) reported earnings of -$0.60 per share for Q3 2026, missing the consensus estimate of -$0.4350. The report was announced on Thursday, August 13, 2026. When is Edesa Biotech's next earnings date? Edesa Biotech's next earnings date is estimated for Friday, December 11, 2026. MarketBeat tracks confirmed and estimated earnings dates for Edesa Biotech on the company's earnings history page. Edesa Biotech Earnings HeadlinesEDSA: Recruitment in Phase 2 Vitiligo Study Set to Get UnderwayAugust 24, 2026 | finance.yahoo.comEdesa Biotech Launches Public Offering of Common Shares, WarrantsAugust 20, 2026 | finance.yahoo.comALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings research points to the first half of 2026 as a particularly rough stretch for certain holdings. Some of America's most popular stocks could take serious damage as a radical market shift plays out. Analysts at Weiss Ratings have identified five names you may want to remove from your portfolio before this unfolds. If any of these are in your portfolio, now is the time to review your positions.October 11 at 1:00 AM | Weiss Ratings (Ad)Edesa Biotech prices $25M equity offeringAugust 20, 2026 | seekingalpha.comEdesa Biotech Announces Pricing of $25.0 Million Public OfferingAugust 19, 2026 | financialpost.comFEdesa Biotech Announces Pricing of $25.0 Million Public OfferingAugust 19, 2026 | globenewswire.comSee More Edesa Biotech Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Edesa Biotech? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Edesa Biotech and other key companies, straight to your email. Email Address About Edesa BiotechEdesa Biotech (NASDAQ:EDSA) is a clinical-stage biopharmaceutical company focused on developing therapeutics for inflammatory and immune-mediated diseases. The company does not have any marketed products and concentrates on advancing investigational treatments through clinical development and regulatory evaluation. Edesa’s lead program has been EB01, a topical therapy being developed for chronic hand eczema, a painful inflammatory skin condition that can significantly affect patients’ daily activities. The company has also evaluated EB05, an antibody-based treatment candidate intended to address excessive inflammation associated with acute respiratory distress syndrome and other serious conditions. The status of individual programs may change as clinical and regulatory work progresses. Edesa is headquartered in Markham, Ontario, Canada, and has conducted development activities in Canada and the United States. The company was founded to pursue therapies for diseases with limited treatment options and has worked with research, clinical, and regulatory partners in advancing its programs. Par Nijhawan has served as the company’s chief executive officer.View Edesa Biotech ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 10/05 - 10/09Q3 Earnings Could Blow Past Consensus—Be Ready for What Comes NextDelta Air Lines Faces a Fuel Crisis—But There's a Silver LiningPalantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November EarningsApplied Digital’s Hidden Moat Could Unlock Massive UpsideLevi's Stock Dip Reveals Value Opportunity Despite Q3 HeadwindsTilray Finds a Path to Growth Without Waiting on U.S. Cannabis Reform Upcoming Earnings Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
